Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma.

Desai, A V; Heneghan, M B; Li, Y; Bunin, N J; Grupp, S A; Bagatell, R; Seif, A E

Desai, A V; Heneghan, M B; Li, Y; Bunin, N J; Grupp, S A; Bagatell, R; Seif, A E.

Affiliation

Desai AV; Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Heneghan MB; Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Li Y; Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Bunin NJ; Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Grupp SA; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Bagatell R; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Seif AE; Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Bone Marrow Transplant ; 51(9): 1204-10, 2016 Sep.

Article in En | MEDLINE | ID: mdl-27159174

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Transplantation Conditioning / Myeloablative Agonists / Neuroblastoma Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male Language: En Journal: Bone Marrow Transplant Journal subject: TRANSPLANTE Year: 2016 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google